Out of our archives – the first percutaneous coronary intervention performed on the patient with acute myocardial infarction 26 years ago. A clinical case report.
Abstract
A clinical case of a patient that suffered from an acute myocardial infarction with ST-segment elevation (STEMI) 26 years ago is presented. Systemic thrombolysis was not possible due to the recent bleeding from the duodenal ulcer. Therefore, the urgent percutaneous coronary revascularization, the first such procedure in Slovenia, was successfully carried out. The PCI was successful, the hospital course uneventful, and the patient did not experience any symptoms for the next two years. Unfortunately, the coronary atherosclerosis progressed later due to unsatisfactory secondary prevention measures; however, the treated infarct-related artery remained patent. The authors explain the strategy of the performed percutaneous procedure and discuss the further development of the treatment. Eleven years later, the primary PCI developed into the dominant reperfusion strategy of the STEMI in Slovenia.
Downloads
References
DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. on behalf of the European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Europ Heart J. 2010;31:943–57.
Kristensen SD, Laut KG, Fajadet J, Kaifoszova Z, Kala P, Di Mario C, et al.; European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014;35:1957-70.
Newby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol. 1996;27:1646-55.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction. Every Minute of Delay Counts. Circulation. 2004;109:1223-5.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
Tadel-Kocjancic S, Zorman S, Jazbec A, Gorjup V, Zorman D, Noc M. Effectiveness of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction from a 5-year single-center experience. Am J Cardiol. 2008;101:162-8.
Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al., on behalf of the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Europ Heart J 2012;doi:10.1093/eurheartj/ehs215.
Cercek B, Horvat M. Arrhythmias with brief, high-dose intravenous streptokinase infusion in acute myocardial infarction. Eur Heart J. 1985;6:109-13.
Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958;71:287–96.
[No authors listed]. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986;1:397-402.
[No authors listed]. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 (second international study of infarct survival) collaborative group. The Lancet. 1988;332:349-60.
[No authors listed] GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet. 1990;336:65-71.
The GUSTO Investigators. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. N Engl J Med. 1993;329:673-82.
Rentrop P, Blanke H, Karsch KR, Wiegand V, Köstering H, Rahlf G, et al. Reopening of infarct-occluded vessel by transluminal recanalisation and intracoronary streptokinase application. Dtsch Med Wochenschr. 1979;104:1438-40.
Meyer J, Merx W, Schmitz H, Erbel R, Kiesslich T, Dörr R, et al. Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation. 1982;66:905-13.
Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, McCallister BD, Gura GM, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J. 1983;106:965-73.
Topol EJ, Eha JE, Brin KP, Shapiro EP, Weiss JL, Riegel MB, et al. Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis. Cathet Cardiovasc Diagn. 1985;11:337-48.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Andersen HR, et al; FINESSE Investigators. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009;2:909-16.
Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569-78.
Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van 't Hof AW, Hoorntje JC, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112-7.
Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573-83.
Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557-67.
Burzotta F, De Vita M, Gu YL, Isshiki T, Lefèvre T, Kaltoft A, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;30:2193-203.
Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al.; TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587-97.
Cannon AD, Roubin GS, Macander PJ, Agrawal SK. Intracoronary stenting as an adjunct to angioplasty in acute myocardial infarction. J Invasive Cardiol. 1991;3:255-8.
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al., for the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without Abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-66.
Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al., for the TYPHOON Investigators. Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction. N Engl J Med. 2006;355:1093-104.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
